Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boyang Sun

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Journal of the National Cancer Center|June 12, 2026
Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastasesDanming He, Yixiang Zhu, Jia Zhong, et al.
Ebiomedicine|January 14, 2025
ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201Li Yuan, Sini Li, Yixiang Zhu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2025
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical StudiesYan Sun, Haochen Yang, Qing Xu, et al.
Science China. Life Sciences|May 17, 2026
Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancerWei Zhuang, Hua Bai, Jie Zhao, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Journal of the National Cancer Center|June 12, 2026
Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastasesDanming He, Yixiang Zhu, Jia Zhong, et al.
Ebiomedicine|January 14, 2025
ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201Li Yuan, Sini Li, Yixiang Zhu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2025
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical StudiesYan Sun, Haochen Yang, Qing Xu, et al.
Science China. Life Sciences|May 17, 2026
Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancerWei Zhuang, Hua Bai, Jie Zhao, et al.
The Lancet. Respiratory Medicine|December 1, 2025
Glecirasib plus sitneprotafib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trialJia Zhong, Jun Zhao, Jianchun Duan, et al.
Pageof 8